Exact sciences corporation stock.
Dec 4, 2023 · Exact Sciences Corporation‘s EXAS shares have surged 35.4% year to date against the industry’s decline of 21.2%. The Medical sector has dropped 8.1% in the said time frame. The company has a ...
Sep 30, 2023 · Company management will host a conference call and webcast on Wednesday, November 1, 2023, at 5 p.m. ET to discuss third-quarter 2023 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international ... Globally, the cancer diagnostics market was worth $172.3 billion in 2022, according to analysts from Grand View Research. And by 2030, they project that will rise to $293.5 billion, averaging a ...Nov 17, 2023 · Get the latest Exact Sciences Corporation (EXAS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. Shares of Exact Sciences (NASDAQ:EXAS) were soaring 9.8% higher as of 3:38 p.m. EDT on Thursday. The company announced on Wednesday that new data for its ...Get Exact Sciences Corp (EXAS.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments
EXACT SCIENCES CORPORATION ANNUAL REPORT ON FORM 10‑K YEAR ENDED DECEMBER 31, 2022 TABLE OF CONTENTS Page No. Part I Item 1. Business 4 Item 1A. Risk Factors 19 Item 1B. Unresolved Staff Comments 52 Item 2. Properties 52 Item 3. Legal Proceedings 53 Item 4. Mine Safety Disclosures 53 Part II Item 5.07-Sept-2023 ... Yet, escalating expenses and competition are major downsides. The stock carries a Zacks Rank #3 (Hold) at present. The Exact Sciences team is ...Third-quarter 2023 financial results. For the three-month period ended September 30, 2023, as compared to the same period of 2022 (where applicable): • Total revenue was $628.3 million, an increase of 20 percent. • Core revenue was $624.8 million, an increase of 23 percent. • Screening revenue was $472.0 million, an increase of 31 percent.
Cologuard uses a biomarker panel which analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform. Cologuard finds colon cancer even in early stages when it is more treatable. 1,2,3* Cologuard is convenient.
Buy candidate since Nov 17, 2023 Loss -1.39% PDF. The EXACT Sciences Corporation stock price gained 0.368% on the last trading day (Wednesday, 22nd Nov 2023), rising from $65.14 to $65.38. During the last trading day the stock fluctuated 3.02% from a day low at $64.84 to a day high of $66.80. The price has been going up and down for this period ...June 7, 2023 at 10:53 AM · 4 min read. Exact Sciences Corporation EXAS is well poised for growth in coming quarters, led by the continued strength across the Screening and Precision Oncology ...10-Jul-2023 ... MADISON, Wis., July 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic ...Shares of Exact Sciences ( EXAS 0.93%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...
Find real-time EXAS - Exact Sciences Corp stock quotes, company profile, news and forecasts from CNN Business.
Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023. Nov 02 + 1 more update. Forecast to breakeven in 2025 Oct 26. No longer forecast ... Lead Independent Director exercised options to buy US$363k worth of stock. Jan 19. Insider notifies of intention to sell stock Jan 13. An Intrinsic Calculation For Exact ...
Company profile page for Exact Sciences Corp including stock price, company news, press releases, executives, board members, and contact informationExact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ...Exact Sciences Corp’s stock is NA in 2023, NA in the previous five trading days and up 56.77% in the past year. Currently, Exact Sciences Corp does not have a price-earnings ratio. Exact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% net profit margin. Year-over-year quarterly sales growth most recently was 20.1%.07-Oct-2020 ... What is Exact Sciences Corporation stock price? On 2023-12-01, Exact Sciences Corporation (EXAS-Q) stock closed at a price of $67.03.EXAS Exact Sciences Corp. Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ) ; Owners. Institutional Owners Retail Ownership Net Long/ ...
Negative. Nikkei 225. 33,451.83. +0.29%. Positive. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.A) real-time stock quotes, news, price and financial ...Exact Sciences Corporation 5505 Endeavor Lane Madison, WI 53719 United States 608 284 5700 https://www.exactsciences.com Sector(s) : Healthcare Industry : Diagnostics & Research Full Time ...Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 3.04% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to date, Exact ...EXAS is the ticker symbol for Exact Sciences Corporation, a company that provides cancer screening and diagnostic test products. The stock price, news, quote, history and performance outlook of EXAS are shown on Yahoo Finance. See the latest earnings report, analyst report, research reports and more. May 15, 2023 · On Nov 8, 2019, Exact Sciences completed the acquisition of Genomic Health for a value of approximately $2.8 billion. Prior to merger, Genomic Health was a prominent provider of genomic-based ...
MADISON, Wis. and CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact …View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Exact Sciences Corporation 5505 Endeavor Lane Madison, WI 53719 United States 608 284 5700 https://www.exactsciences.com Sector(s) : Healthcare Industry : Diagnostics & Research Full Time ...Zacks Equity Research. Exact Sciences (EXAS) closed the most recent trading day at $66.08, moving -1.42% from the previous trading session. This change was narrower than the S&P 500's daily loss ...Exact Sciences Corp. (EXAS) will release its next earnings report on Feb 20, 2024. In the last quarter Exact Sciences Corp. reported -$0.471 EPS in relation to $0 expected by the market. ... Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including ...EXAS is the ticker symbol for Exact Sciences Corporation, a company that provides cancer screening and diagnostic test products. The stock price, news, quote, history and performance outlook of EXAS are shown on Yahoo Finance. See the latest earnings report, analyst report, research reports and more.Company management will host a conference call and webcast on Wednesday, November 1, 2023, at 5 p.m. ET to discuss third-quarter 2023 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international ...The latest EXACT Sciences stock prices, stock quotes, news, and EXAS history to help you invest and trade smarter. ... EXACT Sciences Corp. is a cancer screening and diagnostics company.13-Mar-2021 ... ... CORP ,INCY, BMY, IONIS PHARMACEUTICALS INC ,IONS, EXPERIENCE INVESTMENT CORP-A ,EXPC, ALIBABA GROUP HOLDING-SP ADR ,BABA, ACCOLADE INC ,ACCD ...
MADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, ... Represents severance, accelerated stock-based compensation expense, and …
MADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $486.6 million for the first quarter ended March 31, 2022, compared to $402.1 million for the same period of 2021.
Sep 18, 2023 · In related news, CFO Jeffrey Thomas Elliott recently sold 30,210 shares of Exact Sciences’ stock on August 21st. The average selling price was $82.92 per share, resulting in a total transaction amounting to $2,505,013.20. This transaction was made public through a filing with the SEC, which can be accessed through the provided link. The Exact Sciences pipeline is expanding at a rapid pace. We’re taking the same innovative problem-solving approach that resulted in the multitarget stool DNA test (Cologuard) to tackle a wide array of cancer screening challenges.Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ... 26-Feb-2016 ... 26, 2016 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, ...Stocks Exact Sciences Corp Exact Sciences Corp EXAS Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns...0.67%. $1.47B. EXAS | Complete Exact Sciences Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.EXAS is the ticker symbol for Exact Sciences Corporation, a company that provides cancer screening and diagnostic test products. The stock price, news, quote, history and performance outlook of EXAS are shown on Yahoo Finance. See the latest earnings …In summary, the author projects Exact Sciences Corporation as a "buy" at a 1-year price target of $150 (+13% upside) with strong further upside through 2023. Photo by peterschreiber.media/iStock ...
"Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...Analyst Report: Exact Sciences Corporation Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and ... 5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024. We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT. Find the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and investing.Instagram:https://instagram. best premarket scannerstock trading platform for day tradersmicro flipping housesaustralian stock brokers The company's screening revenue (including laboratory services for Cologuard) saw an even more significant growth of 45% year over year. While Exact Sciences remains unprofitable, there was major ...Exact Sciences Corp. 65.13. Delayed Data. As of Nov 21. -2.15 / -3.20%. Today’s Change. 40.73. Today ||| 52-Week Range. 100.77. forex brokers with dollar5 minimum depositbest funds for rollover ira Dec 1, 2023 · On November 30, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $64.00 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38. ... option trading websites Analyst Report: Exact Sciences Corporation Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and ... Exact Sciences exited third-quarter 2021 with cash and cash equivalents, and marketable securities of $1.22 billion compared with $1.31 billion at the end of second-quarter 2021.Shares Held % O/S Share Change Filing Date; The Vanguard Group, Inc. 17,175: 9.52: 164: 06/30/2023: JPMorgan Investment Management, Inc. 12,307: 6.82: 878: 06/30/2023